BCL2L1 and Thrombocytopenia: A mechanism-based thrombocytopenia due to BCL-XL binding has prevented the clinical development of ABT-263 and has stimulated the development of venetoclax, an analogue with negligible binding capacity for BCL-XL [24–26].